Broshy Eran's Form 4 filing
Theravance Biopharma, Inc. (TBPH) · filed Nov 13, 2025
- Accession no.
- 0001256230-25-000006
- Filed
- Nov 13, 2025
- Trade date
- Nov 11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.07M. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001256230-25-000007 (Nov 14, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Broshy EranCIK 0001256230 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −29,500 | $18.50F1 | −$545,750 | 61,704 | Direct | |
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −15,500 | $17.00F1 | −$263,500 | 46,204 | Direct | |
| Nov 11, 2025 | Ordinary Shares | SSaleDisposed | −14,000 | $18.50F2 | −$259,000 | 46,204 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Ordinary Shares | MOption exerciseAcquired | +14,000 | $10.15 | +$142,100 | 107,878 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
Referenced by the price of 2 transactions in Table I.
- F2
The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
Referenced by the price of 1 transaction in Table I.